Approval Background

The EMA officially approved pretomanid (Doprefla) on July 31, 2020. This decision was based on clinical data for the treatment of multidrug-resistant tuberculosis (MDR-TB), demonstrating that its efficacy and safety profile met European regulatory standards.

Competitive Positioning

Unlike existing injectable treatments, pretomanid can be administered orally, significantly improving patient convenience and treatment adherence. Currently, the European market has limited oral options, making the availability of a new option significant. The adverse event profile is also an important factor when compared to competing drugs.

Insurance Coverage and Market Access Limitations

After approval, each European country's health authorities will separately determine pricing and coverage. Actual patient access may vary by country, as cost-effectiveness must be demonstrated during the HTA evaluation process. In addition, the number of patients with multidrug-resistant tuberculosis is relatively small, which may limit the market size and initial sales, but long-term expansion of the patient base is expected.

Significance and Outlook

This approval represents an important advancement in the pipeline of drugs for multidrug-resistant tuberculosis. Regulatory approval serves as a bridge, transitioning from the clinical development phase to the commercial phase. If approval is expanded to regions outside of Europe, its position in the global market is expected to be strengthened. The availability of a new treatment option is a positive signal for both investors and researchers.